

Company Profile

Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply and the manufacture of patient-specific therapies to drug safety, including blistering. The focus is on six indication areas: oncology, neurology, autoimmunology, ophthalmology, infectiology and hemophilia. The aim of Medios is to ensure the best comprehensive care for patients through partnership-based collaboration and exchange between the various market participants, thus contributing to a sustainable and transparent supply of medicines.

Executive Board



Matthias Gärtner,
CEO & CFO
IT Specialist




Mi-Young Miehler,
COO
Business Economist




Christoph Pruß,
CINO
Pharmacist


Structure and Segments



Consolidated Revenue in €m



Consolidated EBT in €m



CAGR = Compound Annual Growth Rate; *pro forma; ** adjusted for extraordinary expenses

Key Figures

in €m	2019 (IFRS)	2018 (IFRS)	Change
Sales	516.8	327.8	+58%
EBITDA adj.*	17.7	11.7	+51
Margin in %	3.4	3.6	-0,2 PP
EBT adj.*	16.2	11.0	+48%
Margin in %	3.1	3.3	-0,2 PP
Net profit	9.8	4.3	>100%


*adjusted for extraordinary expenses

Basic Information as of February 2021

Share Capital	€20,264,991
No. of shares	20,264,991*
Share class	No-par value bearer shares
WKN/ISIN	A1MMCC/DE000A1MMCC8
Trading places	Regulated Market Frankfurt (Prime Standard)
	Member of the SDAX index

*incl. New Shares from capital increases on 06/04/20, 04/06/20, and 21/01/21

Shareholder Structure as of February 2021



All figures according to voting rights notifications of the notifying parties

Share Price in €



22/11/16 (IPO)

21/01/21

Investment Highlights

- 1. Market:** Highly attractive and strongly growing Specialty Pharma market driven by structural tailwinds
- 2. Positioning:** Uniquely positioned as first mover with clearly defined competitive advantages within the field of individualized medicine
- 3. Business model:** Strong, synergistic business model with clear value-add for stakeholders
- 4. Financials:** Proven financial track record with continuous, profitable asset-light growth
- 5. Strategy:** Highly experienced management team with clear strategy for profitable growth